RENAL OSTEODGSTROPHY
MEDICAL CODING CLASSES IN KOCHI.
Transorze Solutions offers 100% job assurance for trainees to get employed in top companies in your hometown
Medical Coding is converting a diagnosis or symptoms, procedures, and drugs into codes and Medical billing is billing insurance companies and patients for procedures and office visits. Their work is submitted to insurance companies for payment purposes, data collection, research, billing and quality improvement purposes.
RENAL OSTEODGSTROPHY
- N25.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2021 edition of ICD-10-CM N25.0 became effective on October 1, 2020.
- This is the American ICD-10-CM version of N25.0 - other international versions of ICD-10 N25.0 may differ
Renal osteodystrophy is currently defined as an alteration of bone morphology in patients with chronic kidney disease (CKD). It is one measure of the skeletal component of the systemic disorder of chronic kidney disease-mineral and bone disorder (CKD-MBD). The term "renal osteodystrophy" was coined in 1943, 60 years after an association was identified between bone disease and renal failure. The traditional types of renal osteodystrophy have been defined on the basis of turnover and mineralization as follows: mild, slight increase in turnover and normal mineralization; osteitis fibrosa, increased turnover and normal mineralization; osteomalacia, decreased turnover and abnormal mineralization; adynamic, decreased turnover and acellularity; mixed, increased turnover with abnormal mineralization. A Kidney Disease: Improving Global Outcomes report has suggested that bone biopsies in patients with CKD should be characterized by determining bone turnover, mineralization, and volume (TMV system). On the other hand, CKD-MBD is defined as a systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following: 1) abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism; 2) abnormalities in bone turnover, mineralization, volume, linear growth, or strength (renal osteodystrophy); and 3) vascular or other soft-tissue calcification.
Clinical Information
- Decalcification of bone or abnormal bone development due to chronic kidney diseases, in which 1,25-dihydroxyvitamin d3 synthesis by the kidneys is impaired, leading to reduced negative feedback on parathyroid hormone. The resulting secondary hyperparathyroidism eventually leads to bone disorders.
- Metabolic bone disease due to increased bone resorption resulting from the acidosis and secondary hyperparathyroidism of renal insufficiency.
The major treatment modalities for renal osteodystrophy include phosphate binders, vitamin D compounds, and calcimimetics. Aluminum-containing phosphate binders have been shown to be toxic to bone secondary to their effects on bone turnover, mineralization, and bone volume.
Comments
Post a Comment